Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.79 |
| ▸ | DRD3 | P35462 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266921 | 1.00 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL8076233 | 1.00 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7028613 | 0.98 | DRD2 (0.77) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4213402 | 0.98 | DRD2 (0.77) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4208502 | 0.98 | DRD2 (0.77) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL895845 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL895742 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL29547385 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL43366 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL29429678 | 0.88 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1888517-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126939-A1 | NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| EP-0683236-B1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | EP | disclosed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | disclosed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
| EP-0683236-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI (FR) | 1995-11-22 | — | — | EP | disclosed |
| US-5214156-A | Central nervous system disorders, dopamime receptor activity | THE UPJOHN COMPANY (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0334538-B1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0407416-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1991-01-16 | — | — | EP | disclosed |
| WO-1989009050-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1989-10-05 | — | — | WO | disclosed |
| EP-0334538-A1 | Therapeutically useful tetralin derivatives | THE UPJOHN COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | DRD2 57/4885DRD3 78/4885ADRA1A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.